Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOLT-203 in Pediatric Type 1 Primary Hyperoxaluria
NCT06892301Phase 1Active, not recruiting
- Start
- Feb 2025
- Primary completion
- Jul 2026
- Modality
- Gene Silencing, CRISPR-Cas9, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YOLT-203 in Primary Hyperoxaluria Type 1 (PH1). Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Feb 2025; status: active, not recruiting.
02
Drugs
YOLT-203
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NCT06892301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892301.